Pagina de literatura medicala
www.bloodjournal.org by guest on September 29, 2015
How I treat high-risk myeloma
Sagar Lonial, Lawrence H. Boise, and Jonathan Kaufman
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory
University, Atlanta, GA
The treatment of patients with myeloma has dramatically changed over the past
decade due in part to the development of new agents and myeloma-specific
targets. Despite these advancements, a group for whom the long-term benefit
remains less clear are patients with genetically or clinically defined high-risk
myeloma. In order to successfully treat these patients, it is important to first
identify these patients, treat them with aggressive combination therapy, and
employ the use of aggressive long-term maintenance therapy. Future
directions include the use of new immunebasedtreatments (antibodies or cellular
based therapies) as well as target-driven approaches. Until these treatment
approaches are better defined, this review will provide a potential treatment
approach for standard- and high-risk myeloma that can be followed using agents
and strategies that are currently available with the goal of improving progressionfree and overall survival for these patients today.
(Blood. 2015;126(13):1536-1543)
Pentru mai multe informații va rugam sa ne contactați la adresa: medinfo-romania@amgen.com
Material oferit cu sprijinul AMGEN
RO-NP-CARF-0915-115285